Microsites · healthcareJul 202610 min read326 words

Mirror sites (1:1 microsites) for Series B companies: scaling without breaking for healthcare and life sciences

How Series B companies scale mirror sites (1:1 microsites) across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies.

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install mirror sites (1:1 microsites) has to reflect that reality from day one.

Series B is the stress test for mirror sites (1:1 microsites). What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.

The Series B move is to separate the model owner from the operators. One senior human owns strategy, meeting rate from account-specific URLs, and the weekly review; a small team runs the machine.

Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Mirror sites (1:1 microsites) is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.

The Series B failure mode of mirror sites (1:1 microsites) is using them as brochures instead of sales rooms, amplified by headcount. Fix the root cause; do not paper over it with more people.

Compensation begins to matter now. Pay operators on meeting rate from account-specific URLs outcomes, not on effort. Effort-based comp at Series B produces theatre.

A well-run mirror sites (1:1 microsites) function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing mirror sites (1:1 microsites) properly rather than half-heartedly across three vendors.

mirror sites1:1 micrositespersonalized landing pagesmirror sites for series Bscaling GTMmirror sites for healthcare and life scienceshealthcare mirror siteshealthcare and life sciences growth

Frequently asked questions

Microsites · healthcare — answered

Does mirror sites (1:1 microsites) work for healthcare and life sciences?
Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
How does mirror sites (1:1 microsites) change at Series B?
Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
When should we expand to a second region?
After the first region delivers two straight quarters of defensible meeting rate from account-specific URLs.
What compensation model works for mirror sites (1:1 microsites) operators at Series B?
Outcome-linked on meeting rate from account-specific URLs, not activity-based.
What is the Series B stress point?
Using them as brochures instead of sales rooms, amplified by headcount. Fix the root, not the symptom.
What is the healthcare specific pitfall with mirror sites (1:1 microsites)?
Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.

Growth Broker editorial

Filed under microsites · healthcare

Up next

Mirror sites (1:1 microsites) trends to watch in 2026 for healthcare and life sciences

Read piece

Ready to broker your growth?

Book a Growth Call